Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma

Neeraj Agarwal, Joaquim Bellmunt, Benjamin L. Maughan, Kenneth M. Boucher, Toni K. Choueiri, Angela Q. Qu, Nicholas J. Vogelzang, Ronan Fougeray, Guenter Niegisch, Peter Albers, Yu Ning Wong, Yoo Joung Ko, Srikala S. Sridhar, Srinivas K. Tantravahi, Matthew D. Galsky, Daniel P. Petrylak, Ulka N. Vaishampayan, Amitkumar N. Mehta, Tomasz M. Beer, Cora N. SternbergJonathan E. Rosenberg, Guru Sonpavde

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences